LXRX - レキシコン・ファ―マシュ―ティカルズ （Lexicon Pharmaceuticals Inc.） レキシコン・ファ―マシュ―ティカルズLXRXのチャート
LXRXの企業情報
| symbol | LXRx |
|---|---|
| 会社名 | Lexicon Pharmaceuticals Inc. （レキシコン・ファ―マシュ―ティカルズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 レキシコン・ファーマシューティカルズ(Lexicon Pharmaceuticals Inc.)はヒトの疾患の画期的な治療法の開発と商品化に従事するバイオ医薬品会社である。その薬物プログラムには、XERMELO（テロトリスタットエチル）、ソタグリフロジン、LX2761およびLX9211が含まれる。また、臨床および前臨床開発の各段階に多くの追加の化合物を有する。XERMELOは、SSA療法によって不適切に制御される成人のソマトスタチン類似体（SSA）療法と組み合わせて、カルチノイド症候群下痢の治療のためにFDA（食品医薬品局）によって承認された経口送達された小分子化合物である。同社は1型と2型糖尿病の治療薬として、経口送達される小分子薬物候補であるソタグリフロジンを開発中である。LX2761は、糖尿病の治療のために開発中の経口送達小分子化合物である。LX9211は、神経障害性疼痛の治療のために開発中の経口送達小分子化合物である。 レキシコン・ファ―マシュ―ティカルズは米国のバイオ医薬品メ―カ―。ヒト疾患の医薬品の発見と開発に焦点を当てる。主に、糖尿病、カルチノイド症候群、過敏性大腸炎、緑内障、デュシェンヌ型筋ジストロフィ―などの治療薬の臨床や研究を行う。本社はテキサス州ザ・ウッドランズ。 Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients' lives. Through its Genome5000™ program, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to safely and effectively treat disease. Lexicon advanced one of these medicines to market and has a pipeline of promising drug candidates in discovery and clinical and preclinical development in neuropathic pain, heart failure, diabetes and metabolism and other indications. |
| 本社所在地 | 8800 Technology Forest Place The Woodlands TX 77381 USA |
| 代表者氏名 | Raymond Debbane レイモンド・デブーン |
| 代表者役職名 | Independent Chairman of the Board |
| 電話番号 | +1 281-863-3000 |
| 設立年月日 | 34881 |
| 市場名 | NASDAQ National Market System |
| ipoyear | ―年 |
| 従業員数 | 174人 |
| url | www.lexpharma.com |
| nasdaq_url | https://www.nasdaq.com/symbol/lxrx |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -124.99800 |
| 終値（lastsale） | 9.34 |
| 時価総額（marketcap） | 988906254.76 |
| 時価総額 | 時価総額（百万ドル） 921.14390 |
| 売上高 | 売上高（百万ドル） 98.94900 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 956.54890 |
| 当期純利益 | 当期純利益（百万ドル） -139.88100 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Lexicon Pharmaceuticals Inc. revenues increased 28% to $39M. Net loss increased 10% to $76.8M. Revenues reflect Net product revenue increase from $4.6M to $12.8M Collaborative agreements increase of 1% to $26M Royalties and other revenue increase from $64K to $160K. Higher net loss reflects Interest expense increase from $3.2M to $10.3M (expense). |
LXRXのテクニカル分析
LXRXのニュース
Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX) Stock Forecast For 2022: Bullish Signs Point To $16.00 Per Share 2022/08/17 11:00:00 Marketing Sentinel
In the last trading session, 1.06 million Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) shares changed hands as the company’s beta touched 1.51. With the company’s per share price at $3.28 changed hands at -$0.15 or -4.37% during last session, the market valuation stood at $524.37M. LXRX’s last price was a discount, traded about -92.99% off its 52-week … Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX) Stock Forecast For 2022: Bullish Signs Point To $16.00 Per Share Read More »
A Recovery in the Works? Analysts Upgrade or Downgrade Lennar, RealReal, Six Flags and More 2022/08/12 14:50:20 24/7 Wall street
Friday''s additional top analyst upgrades and downgrades were on Ciena, Lennar, Lexicon Pharmaceuticals, Mister Car Wash, PagerDuty, RealReal, Six Flags and more.
LXRX stock gains; Piper Sandler sees “blockbuster potential” for key assets (NASDAQ:LXRX) 2022/08/12 14:34:08 Seeking Alpha
The shares of Woodlands, Texas-based biotech Lexicon Pharmaceuticals (LXRX) gained ~15% after Piper Sandler launched its coverage with an Overweight recommendation citing the…
Piper Sandler Starts Lexicon Pharmaceuticals at Overweight 2022/08/12 07:43:05 Investing.com
https://www.investing.com/news/pro/piper-sandler-starts-lexicon-pharmaceuticals-at-overweight-432SI-2870978
After A 12.08% Jump In The Last Week, Does Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX) Still Make Sense To Buy? 2022/08/05 11:00:00 Marketing Sentinel
During the last session, Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX)’s traded shares were 2.0 million, with the beta value of the company hitting 1.50. At the end of the trading day, the stock’s price was $2.69, reflecting an intraday loss of 0.00% or $0.0. The 52-week high for the LXRX share is $6.33, that puts it down … After A 12.08% Jump In The Last Week, Does Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX) Still Make Sense To Buy? Read More »
After A 12.08% Jump In The Last Week, Does Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX) Still Make Sense To Buy? 2022/08/05 11:00:00 Marketing Sentinel
During the last session, Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX)’s traded shares were 2.0 million, with the beta value of the company hitting 1.50. At the end of the trading day, the stock’s price was $2.69, reflecting an intraday loss of 0.00% or $0.0. The 52-week high for the LXRX share is $6.33, that puts it down … After A 12.08% Jump In The Last Week, Does Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX) Still Make Sense To Buy? Read More »
Lexicon Pharmaceuticals, Inc. (LXRX) CEO Lonnel Coats on Q2 2022 Results - Earnings Call Transcript 2022/08/03 03:30:37 Seeking Alpha
Lexicon Pharmaceuticals, Inc. (NASDAQ:NASDAQ:LXRX) Q2 2022 Earnings Conference Call August 2, 2022 17:00 ET Company Participants Mike Kelly - Investor Relations Lonnel Coats - Chief…
Recap: Lexicon Pharmaceuticals Q2 Earnings 2022/08/02 20:47:42 Benzinga
Lexicon Pharmaceuticals (NASDAQ: LXRX ) reported its Q2 earnings results on Tuesday, August 2, 2022 at 04:00 PM. Here''s what investors need to know about the announcement. Earnings Lexicon Pharmaceuticals reported in-line EPS of $-0.16 … Full story available on Benzinga.com
Lexicon Pharmaceuticals GAAP EPS of -$0.16 in-line, revenue of $0.04M misses by $0.06M (NASDAQ:LXRX) 2022/08/02 20:32:54 Seeking Alpha
Lexicon Pharmaceuticals press release (LXRX): Q2 GAAP EPS of -$0.16 in-line.Revenue of $0.04M (-80.0% Y/Y) misses by $0.06M.“We received acceptance last week of our New Drug…
Lexicon Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update 2022/08/02 20:01:00 GlobeNewswire
Sotagliflozin New Drug Application for Heart Failure Accepted for Review by FDA, with PDUFA Action Date Anticipated in May 2023
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Investor Notice: Investigation over Potential Wrongdoing 2022/05/09 16:00:00 SBWire
An investigation on behalf of investors in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) shares over potential wrongdoing at Lexicon Pharmaceuticals, Inc. was announced. San Diego, CA -- ( SBWIRE ) -- 05/09/2022 -- Certain directors of Lexicon Pharmaceuticals, Inc are under investigation over potential breaches of fiduciary duties. Investors who purchased shares of Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) and have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm concerns whether certain Lexicon Pharmaceuticals directors breached their fiduciary duties and caused damage to the company and its shareholders. The Woodlands, TX based Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. On February 28, 2022, Lexicon Pharmaceuticals, Inc. announced the voluntary withdrawal of the Company''s New Drug Application for its glucose regulation drug, sotagliflozin, in order to correct a technical issue with the submission that had been recently identified by the Company.
Lexicon Pharmaceuticals, Inc. (LXRX) CEO Lonnel Coats on Q1 2022 Results - Earnings Call Transcript 2022/05/05 14:53:02 Seeking Alpha
Lexicon Pharmaceuticals, Inc. (NASDAQ:NASDAQ:LXRX) Q1 2022 Results Conference Call May 05, 2022 08:00 AM ET Company Participants Charles Schultz - Investor Relations Lonnel Coats -…
Lexicon: Q1 Earnings Snapshot 2022/05/05 10:19:33 mySA
THE WOODLANDS, Texas (AP) _ Lexicon Pharmaceuticals Inc. (LXRX) on Thursday reported a loss of $23.5 million in its first quarter. On a per-share basis, the The Woodlands, Texas-based company said it had a loss of 16 cents. The drugmaker posted revenue of $37,000 in the period. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on LXRX at https://www.zacks.com/ap/LXRX
Lexicon Pharmaceuticals GAAP EPS of -$0.16 beats by $0.01, revenue of $0.04M misses by $0.01M 2022/05/05 10:11:23 Seeking Alpha
Lexicon Pharmaceuticals press release (LXRX): Q1 GAAP EPS of -$0.16 beats by $0.01.Revenue of $0.04M (+33.3% Y/Y) misses by $0.01M.As of March 31, 2022, Lexicon had $86.5 million…